SG&A Efficiency Analysis: Comparing AbbVie Inc. and Genmab A/S

SG&A Efficiency: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding operational efficiency is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of AbbVie Inc. and Genmab A/S from 2014 to 2023. Over this period, AbbVie Inc. consistently reported higher SG&A expenses, peaking in 2022 with a 65% increase from 2014. In contrast, Genmab A/S, while starting with significantly lower expenses, saw a dramatic rise, culminating in a 4,000% increase by 2023. This stark contrast highlights AbbVie's established market presence and Genmab's rapid growth trajectory. Such insights are invaluable for investors and industry analysts seeking to understand the financial strategies and market positioning of these pharmaceutical giants. As the industry evolves, monitoring these trends will be key to predicting future performance and strategic shifts.